user-avatar
MarketScreener

Novartis U.S. shares decline after MS pill trial data disappoint

Two Phase 3 trials showed the drug reduced the annualized relapse rate by 35.2% and 31.2% compared with Aubagio. Roche's competing fenebrutinib posted reductions of 51.1% and 58.5%.